Observational studyMedicine2017
Heterotopic ossification related to the use of recombinant human BMP-2 in osteonecrosis of femoral head.
Observational study in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Orthobiologic therapies delay the need for hip arthroplasty in patients with avascular necrosis of the femoral head: A systematic review and survival analysis.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2025Pooled it
- CORR Synthesis: What Is the Evidence for Joint-saving Procedures in ARCO Stage III Osteonecrosis of the Femoral Head?Clinical orthopaedics and related research · 2026Article
- Enhancement of In Vivo Bone Regeneration by the Carbohydrate Derivative DP2.Pharmaceuticals (Basel, Switzerland) · 2025Article
- EP4 receptor stimulation in combination with core decompression therapy enhanced bone regeneration in a canine model of osteonecrosis of femoral head.Frontiers in bioengineering and biotechnology · 2025Article
- The Categorization of Perinatal Derivatives for Orthopedic Applications.Biomedicines · 2024Review
- Local BMP2 hydrogel therapy for robust bone regeneration in a porcine model of Legg-Calvé-Perthes disease.NPJ Regenerative medicine · 2023Article
- Bone tissue engineering for treating osteonecrosis of the femoral head.Exploration (Beijing, China) · 2023Review
- Local Administration of Bone Morphogenetic Protein-2 Using a Hydrogel Carrier for Robust Bone Regeneration in a Large Animal Model of Legg-Calvé-Perthes disease.Research square · 2023Article
- BMP-2 promotes fracture healing by facilitating osteoblast differentiation and bone defect osteogenesis.American journal of translational research · 2023Article
- Revolutionizing bone regeneration: advanced biomaterials for healing compromised bone defects.Frontiers in aging · 2023Review
- Multiple Drilling with Recombinant Human Bone Morphogenetic Protein-2 in Korean Patients with Non-Traumatic Osteonecrosis of the Femoral Head: A Prospective Randomized Pilot Study with a Minimum Two-Year Follow-Up.Journal of clinical medicine · 2022Article
- Cryogel Scaffold-Mediated Delivery of Adipose-Derived Stem Cells Promotes Healing in Murine Model of Atrophic Non-Union.Frontiers in bioengineering and biotechnology · 2022Article
- Emerging roles of growth factors in osteonecrosis of the femoral head.Frontiers in genetics · 2022Review
- Three-dimensional printed polylactic acid scaffold integrated with BMP-2 laden hydrogel for precise bone regeneration.Biomaterials research · 2021Article
- Critical implication of the PTEN/PI3K/AKT pathway during BMP2-induced heterotopic ossification.Molecular medicine reports · 2021Article
- Polymer Scaffolds-Enhanced Bone Regeneration in Osteonecrosis Therapy.Frontiers in bioengineering and biotechnology · 2021Review
- Heterotopic ossification in a patient with diffuse idiopathic skeletal hyperostosis: Input from histological findings.European journal of histochemistry : EJH · 2020Article
- Engineered three-dimensional scaffolds for enhanced bone regeneration in osteonecrosis.Bioactive materials · 2020Article
- Functionalized Scaffold and Barrier Membrane with Anti-BMP-2 Monoclonal Antibodies for Alveolar Ridge Preservation in a Canine Model.BioMed research international · 2020Article
- Bone Morphogenetic Protein-6 Attenuates Type 1 Diabetes Mellitus-Associated Bone Loss.Stem cells translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the wide use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in bone defect, its application in treating osteonecrosis of femoral head (ONFH) is yet to be elucidated. The heterotopic ossification (HO) after rhBMP-2 usage in some orthopedic surgeries has been reported previously; however, only a few studies describe this complication in the treatment of ONFH.The present study investigated whether the rhBMP-2 application would increase the risk of HO formation in selected ONFH patients with nonvascularized bone grafting surgery and enhance the surgical results of nonvascularized bone grafting as compared to patients who did not receive intraoperative rhBMP-2.A retrospective analysis was performed on 94 patients (141 hips) who, with Association Research Circulation Osseous (ARCO) stages IIb, IIc, and IIIa ONFH, underwent nonvascularized bone grafting surgery. The first 46 patients (66 hips) received intraoperative rhBMP-2. The postoperative radiographic results (X-ray and CT scan) and Harris hip score (HHS) were reviewed in each patient to record the incidence of HO formation and evaluate the clinical efficacy of rhBMP-2, respectively.HO formation frequently occurred in patients receiving intraoperative rhBMP-2 (8/66 hips) than those not receiving the protein (1/75 hips) (P = .02). HHS improved from preoperatively at the final follow-up (P < .01) in the BMP-positive group, with a survival rate of 83.3%. In the BMP-negative group, the HHS improved from preoperatively at the end of the follow-up (P < .01), and the survival rate was 72.0%.rhBMP-2 has osteoinductive property and might serve as an adjuvant therapy in the surgical treatment of ONFH. However, the incidence of HO formation might increase when used in high doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.